Shaping the Future of Regenerative Medicine
Founded in 2023, officially becoming a spin-off in 2024, 4Tissue BV is a groundbreaking venture spun from Ghent University, Ghent University Hospital and Vrije Universiteit Brussel (VUB). The venture holds an innovative proprietary technology in the polymer field and has assembled a robust interdisciplinary team of MDs, regulatory experts, and experienced business and product developers. Its lead product Gelinject© is an injectable hydrogel to improve cell-survival in combination with lipofilling procedures. The solution caters to the growing demand for natural (autologous) alternatives in the breast tissue replacement market - a sector valued at billions.
Breast cancer is the most common cancer among women, with approximately 2.3 million new cases each year - affecting 1 in 8 women. In Europe, 60% of women undergoing mastectomy opt for reconstructive breast surgery, but existing methods are often complex and require multiple surgeries or treatments.
In response to the critical need for safer, more effective, and natural breast reconstruction treatments following breast cancer treatment, 4Tissue's hydrogel tissue mimic technology promotes natural cell regeneration. Unlike traditional implants or flap surgeries, 4Tissue's minimally invasive, injectable solution supports the body's natural tissue regeneration process, delivering durable and predictable results.
Milestones
- 2024: raising €2M in seed funding
- 2025: winner of Women TechEU programme
- 2025: securing €1.5M in funding and appointing Dr. Katleen Verleysen as independent chair of the board
- 2025: An Van Den Bulcke, 4 Tissue's co-founder and Chief Business Officer, selected for the prestigious EIC Women Leadership Programme, Cohort 8
